Clinical trials: Inflammatory Breast Cancer
Breast Cancer
NOV-002, Doxorubicin, Cyclophosphamide, and Docetaxel in Women With Newly Diagnosed Stage II or IIIC Breast Cancer
RATIONALE: Oxidized glutathione (NOV-002) may stimulate the immune system in different ways and stop tumor cells from growing. Drugs used in chemotherapy, such as doxorubicin, cyclophosphamide, and docetaxel, work in different…
- Trial name
- NCT00499122
- Testing
- Cyclophosphamide, Docetaxel, Doxorubicin
- Where
- 2 sites in United States
- Volunteers
- 41 people
- Sponsor
- University of Miami
Bilateral Breast Carcinoma, Breast Inflammatory Carcinoma
Multi-epitope Folate Receptor Alpha Peptide Vaccine, GM-CSF, and Cyclophosphamide in Treating Patients With Triple Negative Breast Cancer
This randomized phase II trial studies how well multi-epitope folate receptor alpha peptide vaccine, sargramostim (GM-CSF), and cyclophosphamide work to prevent the recurrence of stage 1-3 triple negative breast cancer.
- Conditions
- Bilateral Breast Carcinoma, Breast Inflammatory Carcinoma, Stage IB Breast Cancer AJCC v7, Stage II Breast Cancer AJCC v6 and v7
- Trial name
- NCT03012100
- Testing
- Cyclophosphamide, Laboratory Biomarker Analysis, Multi-epitope Folate Receptor Alpha Peptide Vaccine
- Where
- 12 sites in United States
- Volunteers
- 280 people
- Sponsor
- Academic and Community Cancer Research United
Breast Cancer
Chemotherapy and Stem Cell Transplantation in Treating Patients With Stage IIIB Breast Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of…
- Trial name
- NCT00003042
- Testing
- filgrastim, cisplatin, cyclophosphamide
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- City of Hope Medical Center
Breast Inflammatory Carcinoma, Recurrent Breast Inflammatory Carcinoma
Grapiprant and Eribulin for the Treatment of Metastatic Inflammatory Breast Cancer
This phase Ib/II trial tests the safety and side effects of grapiprant and eribulin and whether they work to shrink tumors in patients with inflammatory breast cancer that has spread to other places in the body (metastatic).
- Conditions
- Breast Inflammatory Carcinoma, Recurrent Breast Inflammatory Carcinoma, Stage IV Breast Inflammatory Carcinoma
- Trial name
- NCT05041101
- Testing
- Eribulin Mesylate, Grapiprant
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- M.D. Anderson Cancer Center
Early Breast Cancer, Locally Advanced Breast Cancer
A Study to Evaluate Patient Preference for Home Administration of Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administration in Participants With Early or Locally Advanced/Inflammatory HER2-Positive Breast Cancer
This is a Phase IIIb, multinational, multicenter, randomized, open-label study to evaluate patient preference of the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous use (PH FDC SC) administration in the home…
- Conditions
- Early Breast Cancer, Locally Advanced Breast Cancer, Inflammatory Breast Cancer
- Trial name
- ProHer (NCT05415215)
- Testing
- Fixed Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Use (PH FDC SC), Pertuzumab IV, Trastuzumab IV
- Where
- 45 sites in Argentina, Bosnia and Herzegovina and 15 more
- Volunteers
- 346 people
- Sponsor
- Hoffmann-La Roche
Inflammatory Breast Cancer, Invasive Ductal Breast Carcinoma
Accelerated Radiation Therapy After Surgery in Treating Patients With Breast Cancer
This phase II trial studies how well giving accelerated radiation therapy (RT) after surgery works in treating patients with breast cancer. RT uses high energy x rays to kill tumor cells.
- Conditions
- Inflammatory Breast Cancer, Invasive Ductal Breast Carcinoma, Invasive Lobular Breast Carcinoma, Mucinous Ductal Breast Carcinoma
- Trial name
- NCT01417286
- Testing
- External beam radiation therapy
- Where
- 2 sites in United States
- Volunteers
- 69 people
- Sponsor
- Rutgers, The State University of New Jersey
Breast Cancer
Xeloda (Capecitabine) and External Beam Radiation
The goal of this clinical research study is to find out if Xeloda® (capecitabine) and radiation therapy can help to control breast cancer that did not respond well to chemotherapy.
- Trial name
- NCT00916578
- Testing
- Radiation Therapy, Capecitabine
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- M.D. Anderson Cancer Center
Breast Cancer
Neoadjuvant Treatment of Breast Cancer
Study Aims 1. To measure the clinic response rates in patients with breast cancer more than 2 cm and/or lymph node positive breast cancer treated with 2-4 cycles of biweekly doxorubicin, cyclophosphamide with…
- Trial name
- NCT00254592
- Testing
- Doxorubicin, Cyclophosphamide, Carboplatin
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- University of California, Irvine
Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8
Pembrolizumab in Treating Patients With Hormone Receptor Positive, Localized Inflammatory Breast Cancer Who Are Receiving Hormone Therapy and Did Not Achieve a Pathological Complete Response to Chemotherapy
This phase II trial studies how well pembrolizumab works in treating patients with hormone receptor positive inflammatory breast cancer that has not spread to other parts of the body, who are receiving hormone therapy and did not…
- Conditions
- Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Breast Inflammatory Carcinoma, Prognostic Stage IIIB Breast Cancer AJCC v8
- Trial name
- NCT02971748
- Testing
- Pembrolizumab
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- M.D. Anderson Cancer Center
Breast Cancer
Neo-adjuvant Gemcitabine, Epirubicin, ABI-007 (GEA) in Locally Advanced or Inflammatory Breast Cancer
In this trial we will evaluate ABI-007 with gemcitabine and epirubicin, utilizing the biweekly pegfilgrastim support, in order to further improve upon the effectiveness and favorable toxicity of this triplet.
- Trial name
- NCT00193206
- Testing
- Gemcitabine, Epirubicin, Albumin-bound Paclitaxel
- Where
- 13 sites in United States
- Volunteers
- 123 people
- Sponsor
- SCRI Development Innovations, LLC
Breast Cancer
Trastuzumab, Docetaxel, and Carboplatin in Treating Women With Stage II, Stage III, or Inflammatory Breast Cancer
RATIONALE: Monoclonal antibodies, such as trastuzumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00118053
- Testing
- herceptin, carboplatin, docetaxel
- Where
- 9 sites in United States
- Volunteers
- 5 people
- Sponsor
- University of Medicine and Dentistry of New Jersey
Breast Cancer
S0800, Nab-Paclitaxel, Doxorubicin, Cyclophosphamide, and Pegfilgrastim With or Without Bevacizumab in Treating Women With Inflammatory or Locally Advanced Breast Cancer
RATIONALE: Drugs used in chemotherapy, such as paclitaxel albumin-stabilized nanoparticle formulation, doxorubicin, and cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing the cells or by…
- Trial name
- NCT00856492
- Testing
- bevacizumab, pegfilgrastim, cyclophosphamide
- Where
- 366 sites in United States, Puerto Rico
- Volunteers
- 215 people
- Sponsor
- SWOG Cancer Research Network
HER2-positive Breast Cancer, Recurrent Breast Cancer
Pertuzumab, Trastuzumab, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With HER2-Positive Advanced Breast Cancer
This phase II trial studies how well pertuzumab, trastuzumab, and paclitaxel albumin-stabilized nanoparticle formulation work in treating patients with human epidermal growth factor receptor (HER) 2-positive stage II-IV breast…
- Conditions
- HER2-positive Breast Cancer, Recurrent Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer
- Trial name
- NCT01730833
- Testing
- pertuzumab, trastuzumab, paclitaxel albumin-stabilized nanoparticle formulation
- Where
- 3 sites in United States
- Volunteers
- 63 people
- Sponsor
- City of Hope Medical Center
Breast Cancer
A Study of Avastin (Bevacizumab) in Combination With Xeloda (Capecitabine) and Docetaxel in Patients With Inflammatory or Locally Advanced Breast Cancer.
This single arm study will assess the efficacy and safety of combination first-line treatment with docetaxel + Xeloda + Avastin in patients with inflammatory or locally advanced breast cancer.
- Trial name
- NCT00576901
- Testing
- bevacizumab [Avastin], Docetaxel, Xeloda
- Where
- Spain
- Volunteers
- 23 people
- Sponsor
- Hoffmann-La Roche
Breast Cancer
A Study of Avastin (Bevacizumab) Plus Herceptin (Trastuzumab) in Patients With Primary Inflammatory HER2-Positive Breast Cancer.
This single arm study will assess the efficacy and safety of preoperative treatment with Avastin combined with Herceptin-based chemotherapy in patients with primary inflammatory HER2-positive breast cancer.
- Trial name
- NCT00717405
- Testing
- Standard chemotherapy, bevacizumab [Avastin], trastuzumab [Herceptin]
- Where
- 28 sites in France
- Volunteers
- 52 people
- Sponsor
- Hoffmann-La Roche
Breast Cancer
Nintedanib For HER2-Negative Metastatic Inflammatory Breast Cancer (MIBC)
The goal of this clinical research study is to learn if Ofev® (nintedanib, also called BIBF1120) can help to control IBC. The safety of this drug will also be studied. This is an investigational study.
- Trial name
- NCT02389764
- Testing
- BIBF 1120, Phone Call
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- M.D. Anderson Cancer Center
Inflammatory Breast Cancer, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
A Phase 2 Study of Eribulin Followed by AC as Preoperative Therapy for HER2-negative Inflammatory Breast Cancer
This research study is studying a drug called eribulin combined with standard treatment as a possible preoperative treatment for HER2 negative inflammatory breast cancer.
- Trial name
- NCT02623972
- Testing
- Eribulin, Adriamycin, Cyclophosphamide
- Where
- 2 sites in United States
- Volunteers
- 22 people
- Sponsor
- Dana-Farber Cancer Institute
Breast Cancer
TKI258 for Metastatic Inflammatory Breast Cancer Patients
The goal of this clinical research study is to learn if dovitinib can help to control inflammatory breast cancer. The safety of this drug will also be studied.
- Trial name
- NCT01262027
- Testing
- Dovitinib
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- M.D. Anderson Cancer Center
Breast Cancer
Docetaxel Followed by Surgery in Treating Women With Stage II or Stage III Breast Cancer
RATIONALE: Dose-dense scheduling with (peg)filgrastim support may improve the clinical and pathologic complete response rate (pCR) and safety profile of single agent neoadjuvant docetaxel therapy.
- Trial name
- NCT00343512
- Testing
- docetaxel, protein expression analysis, laboratory biomarker analysis
- Where
- 2 sites in United States
- Volunteers
- 34 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Inflammatory Breast Cancer, Male Breast Cancer
Sunitinib Malate, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide Before Surgery in Treating Patients With Stage IIB-IIIC Breast Cancer
This phase II trial studies how well giving sunitinib malate together with paclitaxel, doxorubicin hydrochloride, and cyclophosphamide before surgery works in treating patients with stage IIB-IIIC breast cancer.
- Conditions
- Inflammatory Breast Cancer, Male Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer
- Trial name
- NCT00513695
- Testing
- sunitinib malate, paclitaxel, doxorubicin hydrochloride
- Where
- 7 sites in United States
- Volunteers
- 68 people
- Sponsor
- University of Washington